Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $65.02 USD
Change Today -0.2999 / -0.46%
Volume 3.1M
BMY On Other Exchanges
Symbol
Exchange
Mexico
Sao Paulo
Frankfurt
As of 12:51 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015

Bristol-Myers Squibb Company Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015. Venue: Time Warner Center, New York, United States. Presentation Date & Speakers: May-05-2015, Brian Walsh, Senior Corporate Counsel, Henry Hadad, Vice-President and Deputy General Counsel.

Bristol-Myers Squibb Company - Shareholder/Analyst Call

Annual General Meeting

Bristol-Myers Squibb Company Announces FDA Acceptance of Filing and Review Supplemental Biologics License Application (Sbla) for Opdivo(Nivolumab)

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo(nivolumab)for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted Priority Review for this application. The projected FDA action date is August 27, 2015. Opdivo was first approved by the FDA in December 2014 for patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor. This initial indication was approved under accelerated approval based on tumor response rate and durability of response from CheckMate -037 clinical trial results. This new sBLA accepted by the FDA includes data from CheckMate -066, which evaluated Opdivo in treatment naïve patients with BRAF wild-type advanced melanoma as compared to dacarbazine chemotherapy (DTIC). In the trial, safety and tolerability were well-characterized with fewer treatment-related Grade 3/4 adverse events observed with Opdivo than dacarbazine.

Bristol-Myers Squibb Announces Cash Tender Offer for Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities

Bristol-Myers Squibb Company announced that it has commenced a cash tender offer for up to $400 million aggregate principal amount of specified series of its outstanding debt. Pursuant to the tender offer, Bristol-Myers Squibb is offering to purchase, under certain conditions and subject to certain limitations, its 6.125% Notes due 2038, 5.875% Notes due 2036, 6.80% Debentures due 2026 and 7.15% Debentures due 2023. The early tender date is 5:00 p.m., New York City time, on May 11, 2015, unless extended. The expiration date of the tender offer is 11:59 p.m., New York City time, on May 26, 2015, unless extended or earlier terminated. Holders of notes must validly tender and not validly withdraw their notes before the early tender date to be eligible to receive the total consideration. Tendered notes may only be withdrawn prior to 5:00 p.m., New York City time, on May 11, 2015. Notes tendered after the withdrawal date and before the expiration date may not be withdrawn. Subject to the tender cap, tendered notes will be accepted in the order of the acceptance priority levels. Bristol-Myers Squibb reserves the right, but is not obligated, to increase the tender cap. Tenders of 6.125% Notes and 5.875% Notes will be accepted only in principal amounts equal to $2,000 or integral multiples of $1,000 thereof. Tenders of 6.80% Debentures and 7.15% Debentures will be accepted only in principal amounts equal to $1,000 or integral multiples thereof. The total consideration for each $1,000 principal amount of notes tendered and accepted for payment by Bristol-Myers Squibb pursuant to the tender offer will be determined in the manner described in the Offer to Purchase by reference to a fixed spread specified in the table above for each series of the notes over the yield based on the bid-side price of the U.S. Treasury Security specified in the table above, as calculated by the dealer managers for the tender offer at 2:00 p.m., New York City time, on May 12, 2015. Holders of notes who validly tender their notes after the early tender date will, if such notes are accepted by Bristol-Myers Squibb, receive the tender consideration, which is equal to the total consideration minus $30 per $1,000 principal amount of notes tendered by such holders and accepted for purchase by Bristol-Myers Squibb. Accrued and unpaid interest up to, but excluding, the applicable settlement date will be paid in cash on all validly tendered notes accepted and purchased by Bristol-Myers Squibb in the tender offer.

Bristol-Myers Squibb Company Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year of 2015

Bristol-Myers Squibb Company reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $4,041 million compared to $3,811 million a year ago. Earnings before income taxes were $1,448 million compared to $985 million a year ago. Net earnings were $1,199 million compared to $936 million a year ago. Net earnings attributable to the company were $1,186 million compared to $937 million a year ago. Basic and diluted earnings per share were $0.71 compared to $0.56 per diluted share a year ago. The company reported non-GAAP net earnings attributable to the company of $1.2 billion, or $0.71 per share, in the first quarter, compared to $766 million, or $0.46 per share, for the same period in 2014. The company provided earnings guidance for the full year of 2015. For the period, the company adjusts its 2015 GAAP EPS guidance range from $1.55 to $1.70 to $0.96 to $1.06 primarily due to upfront payments for business development transactions. The company is also adjusting its non-GAAP EPS guidance range from $1.55 to $1.70 to $1.60 to $1.70.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $65.02 USD -0.2982

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $64.33 USD -0.35
Actavis plc $286.98 USD -2.83
Amgen Inc $160.46 USD -1.65
Medtronic PLC $75.08 USD -0.82
Novo Nordisk A/S kr370.60 DKK -11.10
View Industry Companies
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 48.0x
Price/Sales 6.7x
Price/Book 6.9x
Price/Cash Flow 47.8x
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.